The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A first-in-human phase I study of U3-1287 (AMG 888), a HER3 inhibitor, in patients (pts) with advanced solid tumors.
J. Berlin
Research Funding - Pfizer
V. L. Keedy
No relevant relationships to disclose
P. A. Janne
No relevant relationships to disclose
L. Yee
No relevant relationships to disclose
N. A. Rizvi
No relevant relationships to disclose
X. Jin
Employment or Leadership Position - Daiichi Sankyo (U)
Stock Ownership - Daiichi Sankyo
C. Copigneaux
Employment or Leadership Position - Daiichi Sankyo
Stock Ownership - Daiichi Sankyo
Research Funding - Daiichi Sankyo
T. Hettmann
Employment or Leadership Position - U3Pharma
D. M. Beaupre
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
P. LoRusso
Consultant or Advisory Role - Daiichi Sankyo (U)
Research Funding - Daiichi Sankyo